OUP
SelectiveFiled to raiseBala Cynwyd, PABiotechnology, Healthcare, PharmaceuticalsLast fund filed April 2022
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| OUP IV AFF Partnership | April 2022 | $275M | $196M | 19 |
| OUP III AFF PartnershipFiled to raise in 2018, with no closing reported yet. | 2018 | $20M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Matthew Cohen | Selective | None listed | 10 | 3 |
| Marc Singer | Quiet | Data & analytics, Digital health, Manufacturing & industrials | 5 | 0 |
| Robert Adelson | Quiet | Digital health, Enterprise software, Robotics & hardware | 6 | 0 |
| William Harrington | Quiet | Biotech & pharma, Medical devices, Fintech | 7 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of OUP’s own portfolio companies, based on 26 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of OUP’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Osage University Partners | 18 | Atterocor, COLLECTIONS MARKETING CENTER, Embodied, Halfpenny Technologies, Homebase Automation, Hyalex Orthopaedics, MC10, MediSix Therapeutics, MicroTransponder, Neuros Medical, PARACOSM, Pliant.io, PsiKick, Resolve Digital Health, Ribon Therapeutics, Runa, StreetLight Data, TruLite Health |
| U.S Venture Partners | 3 | MicroTransponder, Neuros Medical, Ribon Therapeutics |
| Aperture | 1 | Neuros Medical |
| Breakthrough Energy Ventures | 1 | MC10 |
| Calibrate Ventures | 1 | Embodied |
| Lightstone Ventures | 1 | MediSix Therapeutics |
| Material Impact | 1 | MC10 |
| North Bridge Venture Partners | 1 | MC10 |
| Sigma Prime | 1 | Pliant.io |
| Treo Ventures | 1 | Hyalex Orthopaedics |
A shared board seat: a company where filings name a OUP partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.